Imaging gives clearer picture of cancer drugs' chances of success

April 28, 2014, University of Edinburgh
Drug resistant ovarian cancer cells derived from samples from human patients. The cells were treated with a candidate drug that stops cell growth. The image was acquired using the automated ImageXpress microscopy platform. Blue = cell nucleus; Green = cell-cycle marker (cyclin B); Red = cell-cycle marker (Phophorylated histone H3). Credit: Ashraff Makda (Edinburgh BioQuarter) and Paul Timpson (Garvan Institute of Medical Research, Australia)

The quest for new cancer treatments could be revolutionised by advances in technology that can visualise living cells and tissues, scientists claim.

Leading edge imaging techniques will make it easier to identify which are the most promising new drugs to take forward for patient testing, a review of the technology suggests.

Applying such techniques early in the process could improve the success rate of by helping to rule out drugs that are unlikely to work.

Researchers at the University of Edinburgh are leading the way in using to make the development of new treatments more efficient.

Recent advances mean that scientists can now check how experimental drugs are working inside living cells and in real time.

Using automated microscopes to track fluorescent dyes, researchers can rapidly test thousands of potential drugs in different cancer cell types to find the most promising new treatments.

This pioneering approach – known as phenotypic drug discovery – monitors the effect of a trial drug on the disease as a whole rather than its impact on an individual target protein, which has been the approach until now.

Writing in the journal Nature Reviews Cancer, scientists argue that the new technologies will help to better predict how a drug will work in real life, not just in the test tube.

Currently, just five per cent of drugs tested in clinical trials are approved as therapies for patients. Often drugs do not work in a person as they do in an artificial environment. Sometimes treatments have unexpected side effects that are only picked up in the later stages of the development process.

Report author Dr Neil Carragher, of the Edinburgh Cancer Research UK Centre at the University of Edinburgh, said: "The drug discovery process is hugely expensive and inefficient. In Edinburgh we are leading the way in using biological imaging to streamline the process, allowing us to better select candidates with the lowest risk of side effects and the best chances of success in treating patients."

Explore further: New imaging approach fast tracks drug testing for incurable prostate cancer

More information: J.R.W. Conway, N.O. Carragher, P. Timpson. Developments in preclinical cancer imaging: innovating the discovery of therapeutics. Nature Reviews Cancer, 17 April 2014. DOI: 10.1038/nrc3724

Related Stories

New imaging approach fast tracks drug testing for incurable prostate cancer

March 17, 2014
Cancer Research UK-funded scientists have developed a new way to test the effectiveness of a drug for prostate cancer that has spread to the bone, which is currently incurable, according to research published in the Journal ...

Metal implants may cut chemotherapy side effects, study suggests

February 13, 2014
Cancer patients could one day experience fewer side effects from chemotherapy following a discovery that opens the door for more targeted treatments.

'Dustman' protein helps bin cancer cells

April 21, 2014
Cancer researchers have discovered a new 'dustman' role for a molecule that helps a drug kill cancer cells according to a study, published in the journal Proceedings of the National Academy of Sciences (PNAS), today.

World-first clinical trial launches for advanced bowel cancer

April 2, 2014
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs and new biomarkers ...

Stem cells reach standard for use in drug development

June 11, 2013
Drug development for a range of conditions could be improved with stem cell technology that helps doctors predict the safety and the effectiveness of potential treatments.

Research could help minimize unnecessary exposure to drugs with potential side effects

February 25, 2014
Patients with advanced non-small cell lung cancer (NSCLC) often suffer the challenging side effects of drug regimens that may not have any impact, says Jayson Parker, PhD, a lecturer at U of T Mississauga. Meanwhile pharmaceutical ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.